Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910958 | 0.89 | CNR2 (0.38) | CNR1CNR2FAAHCHRM1ABHD6 | |
| SCHEMBL17970302 | 0.87 | CHRM1 (0.37) | CNR1CNR2FAAHCHRM1ABHD6 | |
| SCHEMBL2578735 | 0.82 | CNR1 (0.37) | CNR1CNR2FAAHCHRM1ABHD6 | |
| SCHEMBL2461985 | 0.82 | CHRM1 (0.33) | CNR1CNR2FAAHCHRM1ABHD6 | |
| SCHEMBL2458257 | 0.80 | BRD4 (0.35) | CNR1CNR2FAAHCHRM1 | |
| SCHEMBL2463804 | 0.79 | CHRM1 (0.36) | CHRM1 | |
| SCHEMBL2467694 | 0.77 | CHRM1 (0.35) | CHRM1 | |
| SCHEMBL7903256 | 0.72 | CHRM1 (0.36) | CNR1CNR2FAAHCHRM1 | |
| SCHEMBL2461332 | 0.71 | CHRM1 (0.36) | CNR1CNR2CHRM1 | |
| SCHEMBL2466827 | 0.71 | MAOB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364298-B1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-9018229-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-9018229-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-RE45108-E1 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-RE45108-E1 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20140045793-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140045793-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20130005675-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20130005675-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-8304546-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304546-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20110269705-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269705-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| WO-2010064735-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005675-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CNR1 291/4885CNR2 746/4885FAAH 1601/4885 |
| US-20110269705-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CNR1 291/4885CNR2 746/4885FAAH 1601/4885 |
| US-20140045793-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CNR1 291/4885CNR2 746/4885FAAH 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.